185 related articles for article (PubMed ID: 29474531)
1. Subtherapeutic Infliximab Trough Levels and Complete Mucosal Healing Are Associated With Sustained Clinical Remission After Infliximab Cessation in Paediatric-onset Crohn's Disease Patients Treated With Combined Immunosuppressive Therapy.
Kang B; Choi SY; Choi YO; Kim MJ; Kim K; Lee JH; Choe YH
J Crohns Colitis; 2018 May; 12(6):644-652. PubMed ID: 29474531
[TBL] [Abstract][Full Text] [Related]
2. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.
Louis E; Mary JY; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Dupas JL; Pillant H; Picon L; Veyrac M; Flamant M; Savoye G; Jian R; Devos M; Porcher R; Paintaud G; Piver E; Colombel JF; Lemann M;
Gastroenterology; 2012 Jan; 142(1):63-70.e5; quiz e31. PubMed ID: 21945953
[TBL] [Abstract][Full Text] [Related]
3. Infliximab Trough Levels Are Associated With Mucosal Healing During Maintenance Treatment With Infliximab in Paediatric Crohn's Disease.
Kang B; Choi SY; Choi YO; Lee SY; Baek SY; Sohn I; Choe BH; Lee HJ; Choe YH
J Crohns Colitis; 2019 Feb; 13(2):189-197. PubMed ID: 30452616
[TBL] [Abstract][Full Text] [Related]
4. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
5. Mucosal Healing in Paediatric Patients with Moderate-to-Severe Luminal Crohn's Disease Under Combined Immunosuppression: Escalation versus Early Treatment.
Kang B; Choi SY; Kim HS; Kim K; Lee YM; Choe YH
J Crohns Colitis; 2016 Nov; 10(11):1279-1286. PubMed ID: 27095752
[TBL] [Abstract][Full Text] [Related]
6. Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn's disease in clinical practice.
Ampuero J; Rojas-Feria M; Castro-Fernández M; Millán-Lorenzo M; Guerrero-Jiménez P; Romero-Gómez M
J Gastroenterol Hepatol; 2016 Jan; 31(1):112-8. PubMed ID: 26173493
[TBL] [Abstract][Full Text] [Related]
7. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease.
Baert F; Moortgat L; Van Assche G; Caenepeel P; Vergauwe P; De Vos M; Stokkers P; Hommes D; Rutgeerts P; Vermeire S; D'Haens G; ;
Gastroenterology; 2010 Feb; 138(2):463-8; quiz e10-1. PubMed ID: 19818785
[TBL] [Abstract][Full Text] [Related]
8. Azathioprine Withdrawal Is Cost-Effective in Patients with Crohn's Disease in Remission on Infliximab and Azathioprine.
Syal G; Melmed GY; Almario CV; Spiegel BMR
Dig Dis Sci; 2023 Feb; 68(2):404-413. PubMed ID: 36512266
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remission.
Papamichael K; Vande Casteele N; Gils A; Tops S; Hauenstein S; Singh S; Princen F; Van Assche G; Rutgeerts P; Vermeire S; Ferrante M
Clin Gastroenterol Hepatol; 2015 Jun; 13(6):1103-10. PubMed ID: 25478919
[TBL] [Abstract][Full Text] [Related]
10. Identifying Patients at High Risk of Loss of Response to Infliximab Maintenance Therapy in Paediatric Crohn's Disease.
Dupont-Lucas C; Sternszus R; Ezri J; Leibovitch S; Gervais F; Amre D; Deslandres C
J Crohns Colitis; 2016 Jul; 10(7):795-804. PubMed ID: 26822611
[TBL] [Abstract][Full Text] [Related]
11. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis.
Colombel JF; Reinisch W; Mantzaris GJ; Kornbluth A; Rutgeerts P; Tang KL; Oortwijn A; Bevelander GS; Cornillie FJ; Sandborn WJ
Aliment Pharmacol Ther; 2015 Apr; 41(8):734-46. PubMed ID: 25728587
[TBL] [Abstract][Full Text] [Related]
12. Risk Factors for Rescue Therapy in Crohn's Patients Maintained on Infliximab After Withdrawal of the Immunomodulator: A Long-Term Follow-Up.
Fischer M; Campbell SC; Calley CSJ; Helper DJ; Chiorean MV; Fadda HM
Dig Dis Sci; 2017 Nov; 62(11):3131-3137. PubMed ID: 28986660
[TBL] [Abstract][Full Text] [Related]
13. Discontinuation of Azathioprine could be considered in pediatric patients with Crohn's disease who have sustained clinical and deep remission.
Jeong TJ; Kim ES; Kwon Y; Kim S; Seo SW; Choe YH; Kim MJ
Sci Rep; 2022 Jan; 12(1):507. PubMed ID: 35017546
[TBL] [Abstract][Full Text] [Related]
14. Change in erythrocyte mean corpuscular volume during combination therapy with azathioprine and infliximab is associated with mucosal healing: a post hoc analysis from SONIC.
Bouguen G; Sninsky C; Tang KL; Colombel JF; DʼHaens G; Kornbluth A; Mantzaris GJ; Rachmilewitz D; Reinisch W; Rutgeerts P; Molenda M; Jannekevan der Woude C; Sandborn WJ
Inflamm Bowel Dis; 2015 Mar; 21(3):606-14. PubMed ID: 25581826
[TBL] [Abstract][Full Text] [Related]
15. Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial.
Louis E; Resche-Rigon M; Laharie D; Satsangi J; Ding N; Siegmund B; D'Haens G; Picon L; Bossuyt P; Vuitton L; Irving P; Viennot S; Lamb CA; Pollok R; Baert F; Nachury M; Fumery M; Gilletta C; Almer S; Ben-Horin S; Bouhnik Y; Colombel JF; Hertervig E;
Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):215-227. PubMed ID: 36640794
[TBL] [Abstract][Full Text] [Related]
16. Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: A retrospective study.
Chauvin A; Le Thuaut A; Belhassan M; Le Baleur Y; Mesli F; Bastuji-Garin S; Delchier JC; Amiot A
Dig Liver Dis; 2014 Aug; 46(8):695-700. PubMed ID: 24893686
[TBL] [Abstract][Full Text] [Related]
17. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease.
Gordon M; Taylor K; Akobeng AK; Thomas AG
Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD010233. PubMed ID: 25081347
[TBL] [Abstract][Full Text] [Related]
18. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
Chande N; Townsend CM; Parker CE; MacDonald JK
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD000545. PubMed ID: 27783843
[TBL] [Abstract][Full Text] [Related]
19. Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study.
Borren NZ; Paulides E; Frinack JL; Olson RN; Willrich MAV; van der Woude CJ; Ananthakrishnan AN
Dig Dis Sci; 2021 Oct; 66(10):3548-3554. PubMed ID: 33037969
[TBL] [Abstract][Full Text] [Related]
20. Early Infliximab Yields Superior Long-Term Effects on Linear Growth in Pediatric Crohn's Disease Patients.
Choi J; Kang B; Kim MJ; Sohn I; Lee HJ; Choe YH
Gut Liver; 2018 May; 12(3):255-262. PubMed ID: 29298460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]